Validation– tag –
-
Bristol Myers Squibb Terminates $380M CAR-T Manufacturing Partnership with Cellares Due to Production Failures for Breyanzi
PharmaLive USA Overview Bristol Myers Squibb (BMS) has ended its $380 million partnership with Cellares, citing Cellares' Cell Shuttle system's failure to meet commercial production requirements for BMS's CAR T-cell immunotherapy, Breyan... -
Yeasen and Porton Advanced Form Strategic Alliance to Fortify CGT Supply Chain and Drive Innovation
Company Announcement China Overview Yeasen Biotechnology and Porton Advanced Solutions have established a strategic partnership aimed at fortifying the cell and gene therapy (CGT) supply chain and fostering innovation. The alliance will ... -
CGT Manufacturers Transform Regulatory Demands into Innovation Drivers: New Strategies for Enhanced Quality and Efficiency
MasterControl USA Overview Cell and gene therapy (CGT) manufacturers are adopting new strategies to leverage stringent regulatory requirements as opportunities for innovation and quality improvement, rather than mere obstacles. Central t... -
FDA Finalizes Flexible CMC Framework, Ending ‘Rule of Three’ for Cell and Gene Therapy Approvals
BioProcess International USA Overview The FDA has issued a finalized "Level 2" guidance document for Chemistry, Manufacturing, and Controls (CMC) flexibilities in cellular and gene therapy (CGT) products, effectively concluding the "Rule... -
FDA Introduces Flexible CMC Guidance for Cell and Gene Therapy Products, Ending ‘Rule of Three’ for Commercial Validation Batches
BioProcess International USA Overview The FDA published and immediately implemented Level 2 guidance, 'CMC Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application' on May 5, 2026. This la... -
FDA Flexibilizes Cell and Gene Therapy CMC Regulations, Eliminating ‘Rule of Three’ to Accelerate Development
BioProcess International USA Overview The U.S. FDA has announced a flexible Chemistry, Manufacturing, and Controls (CMC) guidance for Cell and Gene Therapy (CGT) products, effectively ending the traditional 'Rule of Three' validation req... -
AI and Digital Twin Challenges in GMP Manufacturing: Regulators Demand Audit Trails for Continuously Learning Models
BioPharma APAC Singapore Overview AI and digital twin technologies promise breakthroughs in GMP biomanufacturing, enabling predictive maintenance, real-time release, and high yields. However, regulatory challenges concerning the validati... -
Roche Leverages NVIDIA AI Digital Twins for GLP-1 Biomanufacturing Innovation, Targeting 25-40% Capacity Increase and 15-20% Lead Time Reduction
IntuitionLabs Switzerland Overview Roche announced the integration of NVIDIA's AI and digital twin technologies, including BioNeMo, to optimize its biomanufacturing processes for GLP-1 pharmaceuticals. This initiative aims to create virt... -
CDMO World Releases Validation Guide for Machine Learning in Bioreactor Optimization, Emphasizing Real-Time Control and Data Governance
CDMO World USA Overview CDMO World has published a validation guide analyzing the operational benefits and data integrity risks of applying machine learning (ML) to bioreactor optimization in commercial fermentation processes. The guide ... -
Addressing Bottlenecks in Cell and Gene Therapy Manufacturing: Urgent Need for Quality Control and Supply Chain Optimization
Drug Discovery News USA Overview Cell and gene therapy (CGT) manufacturing faces significant bottlenecks, particularly in autologous cell therapies, due to logistical delays and complex quality control challenges. Frequent issues arise w...
12